Scinai Immunotherapeutics Ltd. (SCNI) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -1.45M | -1.29M | -1.29M | -1.08M | -2.04M | -1.76M | -1.46M | -1.23M | -2.22M | -2.88M | -3.06M | 0 |
| Operating CF Margin % | -297.75% | -333.12% | -333.12% | -522.33% | -1213.1% | -619.01% | - | - | - | - | - | - |
| Operating CF Growth % | -12.78% | 26.76% | 12% | 12.16% | 8.28% | 38.87% | 52.17% | - | -9.02% | 21.53% | -176.83% | 100% |
| Net Income | 3.57M | -2.07M | -2.07M | -2.23M | 10.49M | -2.32M | -2.16M | -2.33M | 3.11M | -3.76M | -3.52M | -528.81K |
| Depreciation & Amortization | 451.77K | 352K | 352K | 499K | 498K | 494.19K | 156K | 84.91K | 145K | 147K | 138K | 0 |
| Stock-Based Compensation | 0 | 135K | 135K | 204K | 145K | 142K | 191K | 453K | 234K | 200K | 252K | 1.6M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -6.08M | 158K | 158K | -24K | -13.11M | 46.81K | 438K | -3.39M | -4.79M | -2.03M | 2.98M | -1.07M |
| Working Capital Changes | 604.36K | 134.5K | 134.5K | 475K | -53K | -119K | -89K | 3.95M | -914K | 2.56M | -2.92M | 0 |
| Change in Receivables | 30.91K | -39.5K | -39.5K | 152K | -2K | -158K | 149K | -208K | -90K | -23K | 30.71K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 198.46K | 0 | 0 | -54K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | 2.74M | -6K | -6K | -23 | -4K | -6K | -2K | -234K | -20K | -377K | -6K | 0 |
| Capital Expenditures | -2.99K | -6K | -6K | -23 | -4K | -6K | -2K | -234K | -20K | -377K | -6K | 0 |
| CapEx % of Revenue | 0.61% | 1.55% | 1.55% | 0.01% | 2.38% | 2.11% | - | - | - | - | - | - |
| Acquisitions | 2.74M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 10.97K | 790.5K | 790.5K | 2M | 8K | 12K | 1.42M | 10.67K | 1.09M | -3.96K | 6.93K | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.97K | 0 | 0 | 0 |
| Equity Issued (Net) | 10.97K | 0 | 0 | 2.01M | 6.36K | 1.98K | 1.44M | -947K | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -947K | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 790.5K | 790.5K | -12.23K | 1.64K | 10.02K | -15.76K | 957.67K | 1.09M | 0 | 6.93K | 0 |
| Net Change in Cash | 1.3M | 1.13M | -2.1M | 926K | -2.04M | -1.75M | -44K | -1.47M | -1.15M | -3.29M | 10.93M | 0 |
| Free Cash Flow | -1.46M | -1.29M | -1.29M | -1.08M | -2.04M | -1.76M | -1.47M | -1.46M | -2.24M | -3.25M | -3.06M | 0 |
| FCF Margin % | -298.37% | -334.67% | -334.67% | -522.33% | -1215.48% | -621.13% | - | - | - | - | - | - |
| FCF Growth % | -12.49% | 26.67% | 11.71% | 26.25% | 8.92% | 45.77% | 52.2% | - | -8.1% | 10.39% | -88.5% | 100% |
| FCF per Share | -1538.11 | -0.81 | -1.60 | -1.33 | -2.42 | -2.77 | -2.89 | -4.86 | -4.78 | -9.63 | -9.47 | - |
| FCF Conversion (FCF/Net Income) | -0.41x | 0.62x | 0.62x | 0.48x | -0.19x | 0.76x | 0.68x | 0.53x | -0.72x | 0.76x | 0.87x | - |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 143K | 108K | 0 | 0 | 725K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |